Design Therapeutics (DSGN) | Finance information

Compare Design Therapeutics

	P/E Ratio	Dividends	Return on Equity	Price-to-Sales	Debt-to-Equity
Design Therapeutics Inc	0	0%	-	-	-
Market Avg	53.2	1.27%	29%	-	1.3
Healthcare Avg	29.7	1.32%	16%	7.3	1.3

$12.00

Target Price by Analysts

172.1% upsideDesign Therapeutics Target Price Details

$0.32

Current Fair Value

92.6% downside

Overvalued by 92.6% based on the discounted cash flow analysis.

Share Statistics

Market cap	$254.23 Million
Enterprise Value	-
Dividend Yield	$0.0 (0.0%)
Earnings per Share	$0.0
Beta	1.77
Outstanding Shares	56,495,039
Avg 30 Day Volume	328,558

Return

Return on Equity	-
Return on Assets	-
Return on Invested Capital	-

Valuation & Multiples

P/E Ratio	0.0
PEG	-
Price to Sales	-
Price to Book Ratio	-
Enterprise Value to Revenue	-
Enterprise Value to EBIT	-
Enterprise Value to Net Income	-
Total Debt to Enterprise	-
Debt to Equity	-

Revenue Sources

No data

ESG Score

No data

About Design Therapeutics Inc

15 employees

Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on the treatment of Friedreich ataxia, foll...